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Abstract: Inflammatory bowel diseases (IBD) are currently considered multifactorial pathologies in
which various combined environmental factors act on a genetic background, giving rise to a chronic
inflammation of the gastrointestinal tract. Among the various environmental factors, it now seems
clear that the diet plays the major role in IBD onset and progression. Several clinical studies have
attempted to understand the impact of diet in the development and progression of these diseases
in order to establish useful guidelines for their management. However, the modest and sometimes
contradictory results did not lead to the definition of shared dietary suggestions. On the other hand,
food fads and recommendations based on anecdotal episodes are often followed by IBD patients to
improve their diet. This review provides a critical overview of existing data on the role of diet as a risk
factor for IBD. The methodology used was that of analyzing the results of clinical studies conducted
on diet and IBD over the last 12 years through PubMed, as well as analyzing the most relevant studies
on nutrients and their possible roles in IBD through the knowledge of the mechanisms by which they
can modulate the microbiota or the intestinal physiology.
Keywords: Inflammatory Bowel Disease (IBD); Mediterranean Diet; Western-style Diet (WSD);
Nutritional Approach
1. IBD and Environmental Risk Factors
The etiology of inflammatory bowel disease (IBD) remains unclear. The most accredited theory
is the interplay between genetic susceptibility and exposure to environmental risk factors, such as
pollution, stress, diet, pathogen infections, antibiotic treatment and cigarette smoking, also known as
the exposome paradigm [1]. Many studies evidence a rise in both the incidence and prevalence of IBD
in traditionally low-incidence areas, such as southern Europe, Asia and most developing countries
where Western lifestyle and nutritional habits are progressively being adopted [2]. The prevalence of
IBD has also increased significantly in the pediatric population [3].
Many studies have concluded that people emigrating from low-prevalence regions, such as
Asia, to high-prevalence countries like northern Europe are at greater risk of developing IBD. This is
especially true for first-generation immigrant children who show similar IBD incidence and prevalence
patterns to the indigenous population [4].
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These findings would seem to reduce the importance of a genetic predisposition to IBD and
incriminate major lifestyle changes for the rising IBD rates observed in developing countries,
in immigrant populations moving to high-prevalence countries, and children in developed countries.
These considerations suggest that environmental factors significantly modify the expression of Crohn’s
Disease (CD) and Ulcerative Colitis (UC). IBD would therefore appear to be a worldwide disease
linked to environmental factors such as the diet, lifestyle and pollutants prevalent in industrialized
urban societies [4,5].
Diet is a key environmental factor. It plays a major role in the homeostasis of the gut
microenvironment, influencing the gut’s microbial composition and functioning, the gut barrier,
host immunity and the gut physiology by regulating gut hormone release [6,7]. The diet in the
developed “Western” world is very different from the traditional diet of previous generations when
the prevalence of IBD was considerably lower. The most radical change has been the switch from a
plant-based to an animal-sourced diet. This radically modified the gut microbiota and microbiome
decreasing the amount of bacteria involved in fiber degradation, such as Prevotella and Treponema. [8,9].
Another important change is the increased presence of xenobiotics in food and especially in meat.
Xenobiotics are chemical substance that are not naturally produced or expected to be present within
the organism and that mainly derive from environmental pollution or from pesticide, widely used in
conventional agriculture. Xenobiotics can undergo the bio-magnification process in intensively farmed
animal meat. In fact, changes in the gut microbiome and xenobiotic metabolism have been found in
children with Crohn’s disease [10].
Recent data suggest that another important change brought about by the Western diet is an overall
higher calorie intake, especially from sugar, refined carbohydrates, animal proteins and ultra-processed
foods. The role of these latter in gut homeostasis is still under investigation [11], and there are not
in-depth studies linking ultra-processed foods and IBD, however, it is becoming increasingly evident
that some food additives have negative effects on the gut microbiota.
In conclusion, diet may well play a key role in both the pathogenesis and clinical course of IBD.
As a result, diet should become an effective tool to optimize the efficacy of the conventional treatment
of these diseases.
2. The Microbiota and IBD
The human gut is colonized by a specific and dynamic subset of trillions of microorganisms.
Fundamental for our body functions, these microorganisms weigh about 1 kg—significantly more
than all the cells of the human body—and contain more than 100 times as many genes as the human
genome. They constitute the so-called ‘gut microbiota’ of the host’s gastrointestinal tract [12].
The human microbiota comprises different types of microorganisms, including bacteria
(prokaryotes), archaea, fungi, protists, and viruses. Its composition differs significantly in the
different regions of the gut. Indeed, the displacement of microbial communities within the intestinal
tract can sometimes give rise to pathologies such as the small intestinal bacterial overgrowth (SIBO)
syndrome [13].
The gut microbiota and its host exist in a symbiotic relationship. Together they form a
sort of “super-organism” with a wide range of functions. These include digesting substrates,
producing nutrients, developing and regulating the immune system, preventing the growth of
harmful microorganisms by forming a barrier against colonization or invasion, and detoxifying certain
xenobiotics [14]. An adequate biodiversity of the microbiota plays an important role not only for the
correct functions of the intestine but also in other organs and systems, such as the enteric and central
nervous system [15]. Brain and microbiota interactions have led to the recognition of a new term
called "microbiota-gut-brain axis". This term refers to a two-way communication system that allows
intestinal microbes to change the physiology of the brain and the brain to modulate the intestinal
functions. The evidence of this two-way communication comes from multiple studies that have
shown that stressful events in an individual’s life can alter the composition of the intestinal microbiota,
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as well as reciprocally, the infection of intestinal pathogenic bacteria can induce anxiogenic behavior in
mice [16,17]. Moreover, impaired responses of the central nervous system to stressors have also been
clearly demonstrated in patients with microbiota alterations due to active Crohn’s disease [18].
Another characteristic of the gut microbiota is its inter-individual variability due to genetic
predisposition and factors such as environmental microbes, geography, climate, sanitation, pollution,
diet and lifestyle (Figure 1). It follows that the composition of an individual’s microbiota changes
continuously in a mutualistic response to extrinsic and intrinsic variables. Excessive alterations of
the gut microbiota lead to an intestinal imbalance between protective and harmful bacteria, called
dysbiosis. This condition seems to be responsible for the inadequate response of the immune system to
both external and intestinal epitopes, and may contribute to the loss of oral tolerance. This imbalance
can have serious effects during infancy and early childhood when the microbiota is still maturing [19].
Dysbiosis may also be a leading contributory cause of several gut microbiota-related diseases, including
IBD [20,21].
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CCK, Cholecystokinin; GIP, Gastric inhibitory polypeptide; 5-HT, 5-hydrox tryptamine or Ser tonin.
While many studies have clearly demonstrated the presence of severe intestinal permeability
alterations during the active phases of IBD, permeability seems to recover during the re ission phase.
It should be noted, however, that modest alterations in intestinal permeability are difficult to be
me sured in vivo [22].
IBD are associated with alterations in the composition of the intestinal microbiota, namely a
significant reduction of bacterial diversity, an increase n several pro-inflammatory components called
“pathobionts”, such as Proteobacteria and Acti ob cteria, and the depletion of “health-promoting”
anti-inflammat ry bacterial genus, such as Faecalibacterium and Roseburia [23].
During the acute phases of IBD, altered intestinal permeability causes commensal bacteria
and microbial antigens to translocate from the lumen to the submucosa, giving rise to local and
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systemic inflammation. These translocations activate the immune cells, which in turn release
numerous pro-inflammatory cytokines, activating an inflammatory loop and inducing chronic intestinal
inflammation [24].
The microbiota’s plasticity allows the gut microbiome to respond rapidly to changes in dietary
patterns. The fermentable carbohydrates, protein, fat, and sugars ingested modulate the levels of
beneficial and harmful microbes, toxic microbial metabolites and protective metabolites, such as
short-chain fatty acids (SCFAs) [25].
Dietary fibers, polysaccharides, sugars (i.e. lactose) and peptides that are not digested by host
enzymes in the upper gut are partly degraded by the gut microbiota in the cecum and colon through a
process called fermentation. The major products of fiber fermentation are SCFAs, in particular, acetate,
propionate, and butyrate [26]. SCFAs play important multifactorial roles in energy homeostasis, host
immune function [25,27] and general gut physiology [25,28] (Table 1). As a result, the amount of SCFAs
synthesized, especially in the colon, has been adopted as an indirect measure of microbiota health [28].
High salt consumption also affects the gut microbiome of both mice and humans by lowering the
intestinal survival of Lactobacillaceae [29].
Table 1. The multifactorial role of the SCFAs in energy homeostasis in host immune function and host
physiology [25,27,28]. GABA, gamma-Aminobutyric acid; CNS, Central Nervous System; ENS, Enteric
Nervous system; PYY, Peptide YY; GLP-1, Glucagon-like peptide-1.
CNS Activity Metabolic Regulations Immune Homeostasis
GABA production in CNS
Modulation of ENS and CNS function
Serotonin biosynthesis
Energy source
Intestinal gluconeogenesis
Antilipolytic activity (WAT)
Lepitin production (WAT)
Release of major appetite and glucose
regulatory peptides (PYY, GPL1) (L-cell)
Enhancement of IL-10 (DC)
IL-18 biosynthesis (IEC)
Treg polarization
Reduction of TNF, IL-6, IFN (DC)
IEC barrier fortification
IgA promotion
The modulation of intestinal microbiota can be also implemented through probiotics. Probiotics
have been defined by the World Health Organization (WHO) as "live microorganisms which, when
administered in adequate quantities, confer health benefits to the host". They can play beneficial effects
on the digestive system, through multiple mechanisms including interference with potential pathogenic
microorganisms, improvement of the barrier function, immunomodulation and the modulation of
neurotransmitter synthesis [30,31]. The impact of probiotics on IBD has been the subject of numerous
studies. Data derived from studies on animal IBD models showed a high potential of different bacterial
strains in modulating the clinical course of experimental IBD. Instead, on humans the experimental
results showed little evidence of efficacy on Crohn’s disease (CD), modest data on Ulcerative Colitis
(UC) but a good support for patients affected by pouchitis, the inflammation of the ileal pouch which
is created in the management of IBD patients [32].
It has recently been demonstrated that several dietary components can alter the intestinal
microbiota. These include xenobiotics belonging to the group of environmental contaminants, but also
additives normally used for the preparation of ultra-processed foods. The xenobiotics capable to
have negative effects on the microbiota include organochlorine pesticides [33], glyphosate [34] and
perfluorooctanesulfonic acid [35]. All these components have been found in human breast milk,
and may therefore negatively modulate the microbial ecology of babies whose unstable microbiota
could rapidly develop into a permanently altered gut environment [35]. The effect of food additives
added to ultra-processed foods will be discussed in detail below.
Studies of IBD-associated microbiome have evidenced the important role played by the gut
environment in the manifestation of IBD. It has also been observed that among the environmental
factors associated with microbiota development and alterations, diet plays a key role in modulating the
composition and functions of the microbiome and epithelial barrier, and may even influence epigenetic
changes. It follows that the food may deeply modulate the microbiome-gut axis and therefore it may
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represent an important therapeutic tool to counteract dysbiosis and modify the natural history of IBD,
bearing out the motto “We are what we eat” [7].
3. Evolution of the Human Diet
The first dramatic change in human nutrition occurred about 10,000 years ago during the Neolithic
age with the transition of the hunter/gatherer society to one based on agriculture and livestock farming.
This change profoundly modified man’s diet. Instead of a wide range of different foods that changed
with the seasons and with the migratory patterns of animals, our diet became restricted to a few
domesticated plants and farmed animal species. For the human metabolism this meant a dramatic
change in glycemic load, fatty acid composition, macro- and micro-nutrient concentration and total
fiber content. Indeed, in evolutionary terms, this dietary change is so recent that the human species
has not had enough time to adapt its gastro-intestinal physiology [36]. Many foods common in the
new diet were completely absent in the hunter/gatherer society. Milk, for example, was consumed only
during breastfeeding, and dairy products were completely absent [37]. The first evidence of dairy milk
consumption has been dated to about 6,000 years ago [2,38]. Cereals are another interesting example.
At the beginning of the Holocene age (12,000–10,000 years ago), cereals—always unrefined—were still
rarely eaten. The first evidence of white flour production has been traced back to around 3500 Before
Christ (BC) in ancient Egypt [39], but the widespread consumption of highly refined flours began only
150–200 years ago [40].
The second truly revolutionary change in the human diet was the introduction of industrialized
food following the Second World War. Driven by the so-called “green revolution”, which made
widespread use of agricultural chemicals, industrialized food production led to a huge rise in the
availability of refined cereals, sugar, cheese, butter and coffee (Figure 2). Before this, sugar had been
a rare component of the human diet. The first evidence of crystallized sugar can be traced back to
500 BC in India [41]. Before that, the only source of sugar had been honey, available in very limited
amounts and only at certain times of the year. Even subsequently, sugar remained a rare commodity.
Before the industrial revolution, the annual average sugar consumption in the United States was 6.8 kg
per person while in 1970 it exceeded 55 kg, and in 2000 stood at 69 kg [42].
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Industrialization and the advent of intensive farming also involved a change in farmed animal
feed. As a result, the quality of farmed meat, and especially its fat content, is today completely different
from the wild animal meat consumed by hunter/gatherers. This is because mammal fat stores are
localized in subcutaneous and abdominal adipose tissue in the form of saturated fatty acids (SFAs),
while polyunsaturated and monounsaturated fatty acids (PUFAs and MUFAs) prevail in the muscles.
It has been estimated that prior to domestication, wild animals consumed most of their subcutaneous
and abdominal fat reserves, with the result that our hunter ancestors ate meat with high levels of
muscle-stored PUFAs and MUFAs and little or no SFAs [43–46]. Industrial farming, on the other hand,
has led to hyper-fed animals with high percentages of accumulated SFAs [45,46].
First extracted around 5000 years ago, vegetable oils were not initially used as a food. It was
only with industrialization and the introduction of new extraction techniques that seed oils became
products for human consumption (Figure 2). With the advent of hydrogenation in 1980, hydrogenated
vegetable fats suddenly became part of our daily diet. Overall, the increase in dietary fat has certainly
had an impact on the microbiota and GI diseases [47].
Salt consumption seems to have started at the beginning of the Neolithic age, although its massive
consumption only began with the industrial revolution. This has led to an inversion of our ingested
sodium/potassium ratio compared to the Neolithic diet. Today, 90% of the salt in the Western-style
diet (WSD) comes from processed foods [36]. Food industrialization has also caused a sharp drop
in the consumption of fruits and vegetables, and therefore fibers, vitamins and potassium [44,48].
In conclusion, industrialization and the resultant change in diet caused a sudden rise in man’s net acid
load after digestion, also known as the Potential Renal Acid Load, PRAL. This is because staple WSD
foods like cheese, refined cereals and meat are net acid producers while the vegetable-rich diet of our
pre-agricultural ancestors was a net base producer [49].
The dramatic change in man’s diet is still ongoing. Ultra-processed foods, recently classified as
the NOVA-4 group [50], are now readily available and today account for over 50% of the total energy
intake of the United States population [11,51].
4. The Western-Style Diet and Its Pro-Inflammatory Foods
Compared to traditional regional diets, such as Mediterranean, Indian, Japanese and South East
Asian, the WSD contains significantly higher amounts of simple refined carbohydrates, saturated fats,
red meat, dairy products and industrialized foods, and a concomitantly lower quantity of vegetables,
fruits, legumes, whole cereals, raw foods and fibers in general (Figure 3). In fact, the WSD consists
mainly of calorie-dense foods high in saturated fats, glycemic carbohydrates and animal proteins.
Many studies have looked at the association between WSD and obesity, hypertension [52], chronic
kidney disease [53] and other non-communicable diseases [54]. Their findings clearly show that the
WSD may promote intestinal inflammation through various mechanisms, including alterations of
the microbiota [55–58]. Although the relationship between the WSD and IBD has been only partially
investigated [59,60], it is nonetheless true that the WSD contains nutrients able to elicit a direct or
indirect pro-inflammatory effect on the intestine through one of the three components involved in
gut physiology: the immune system, the microbiota, and the intestinal barrier. Moreover, the WSD
is low in nutrients and micronutrients with anti-inflammatory and anti-oxidant proprieties. It is
therefore not unreasonable to consider the transition to the WSD, also defined as diet westernization,
as one of the major environmental factors responsible for the rising incidence and prevalence of IBD.
A very interesting in-depth study on the effects of this dietary switch on the intestinal microbiota of
children has been recently published [61]. The authors clearly demonstrate that the gradual increase
of animal proteins (meat and dairy products), saturated fats, and processed and refined foods to the
rural vegetarian diet of urban African children drastically changed their microbial profiles and gut
functioning. The sharp drop in fiber intake as a result of the dietary change was found to lead to
a concomitant fall in microbial populations able to ferment dietary fibers and a sharp rise in other
bacterial groups able to metabolize animal proteins, animal fats and sugars. The westernization of
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the diet has involved and overwhelmed even the traditional oriental diets, such as the Japanese or
that of South East Asia, which are diets geographically associated with a low prevalence of IBD [62].
The potential implications of WSD components on the gut immune system, the microbiota and the
intestinal permeability will be analyzed in detail in the following sections of this review.Nutrients 2019, 11, x FOR PEER REVIEW 7 of 23 
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pyramids. The Mediterranean diet pyramid is inspired by the eating habits of Greece, Southern Italy,
and Spain before 1950s. The principal aspects of this diet include high consumption of fruits, vegetables,
unrefined cereals, legumes and olive oil, moderate to high consumption of fish, moderate consumption
of dairy products and low consumption of non-fish meat.
5. Carbohydrates
Carbohydrates are classified on the basis of their chemical structure into mono- and
di-saccharides (simple sugars, uch as glucose, fructose, suc ose), oligosaccharid s (fructo- and galacto-
oligos ccharides), and polysac rides (starch, cellulose, inulin). A fraction of the carbohydr tes
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ingested remains undigested in the small intestine and passes to the large intestine to be fermented
and/or excreted. For this reason, carbohydrates are also classified according to their absorbability
in the small intestine. For example, simple sugars and starches are hydrolyzed and absorbed in the
small intestine and are therefore known as available carbohydrates. Inulin, fructo-oligosaccharides and
galacto-oligosaccharides, known as resistant starches, are not hydrolyzed in the small intestine but
fermented by the large bowel microbiota, and are therefore called unavailable carbohydrates. Finally,
insoluble fibers including plant cell-wall polysaccharides, such as cellulose and pectin, and some
storage polysaccharides, such as inulin and oligosaccharides, are also called non-digestible components
because they pass through the digestive tract largely intact, exerting a laxative effect by changing the
osmotic properties of the luminal content and by increasing the intestinal fecal mass. The quality
of the carbohydrate ingested, for example, whether mono-, di- or oligo-saccharides, also seems to
impact the clinical course of IBD. In fact, a correlation has been observed between fructose and lactose
malabsorption and IBD severity [59,63]. In light of this evidence, a fructose- and lactose-free diet has
been proposed for IBD patients [59].
Lactose malabsorption is frequently detected in IBD, especially in CD patients. However,
prevalence is ethnicity dependent, being higher among Asian populations. Moreover, although
lactose avoidance may improve symptoms in patients with lactose intolerance, evidence of objective
disease improvement is currently lacking. Studies of a lactose-free diet in IBD patients are currently
underway [59].
High consumption of fermentable carbohydrates such as glucose, fructose, sucrose, lactose or
polyols (sorbitol, mannitol, xylitol and maltitol) has been shown to exceed the intestine’s absorptive
ability, increasing dysbiosis and gut permeability, thus promoting inflammation. These fermentable
carbohydrates, which include oligo-, di-, and monosaccharides and polyol, are known as FODMAPs
(Table 2). Being poorly absorbed, they are rapidly fermented by bacteria in the gut, giving rise to a high
osmotic load. This is the rationale behind the FODMAP-exclusion diet. Firstly proposed for Irritable
Bowel Syndrome (IBS) patients, the FODMAP-exclusion diet was applied for a limited period to a
few IBD patients [64] in an attempt to alleviate their IBS-like symptoms, such as bloating, flatulence,
crampy pain, and diarrhea, but proved very limited benefit. Moreover, since undernutrition is a
common feature of IBD, the use of this very restrictive diet should be carefully considered [64].
Table 2. Carbohydrates included or excluded in the low-FODMAPs diet.
Food Group Include Exclude
Fruit
Bananas, strawberry, raspberry, blueberry, orange,
mandarin, clementine, cantaloupe, grapes, melons, lemon,
lime, kiwi, passion fruit
Apple, applesauce, apricots, blackberries, cherries,
nectarines, pears, peach, plum, prune, watermelon,
grapefruit, dried fruit
Vegetables
Carrots, celery, corn, alfalfa, bean sprouts, bell pepper,
broccoli (<1/2 cup), bok choy, cucumber, eggplant, green
bean, kale, lettuce, potato, spinach, spring onion (green
top), squash, tomato, turnip, zucchini
Brussels sprouts, asparagus, avocado, beetroot,
cauliflower, cabbage, garlic, leek, mushroom, onion,
pea shallot, snow pea, sweet corn, sweet potato
Grains Rice, oats Wheat, rye
Legumes Certain legumes (soya) Many legumes (chickpeas, lentils, beans)
Dairy Lactose-free yoghurt and milk; almond, coconut, rice orsoy “milk”, hard cheese, low-lactose cheese
Cow, goat, sheep milk, buttermilk, soymilk, soft
cheese cream and ice cream
Beverage Fruit juice and vegetable juices from permitted foods, wine Soft drinks, sports drinks, fruit juice and vegetablejuices from unpermitted foods, alcohol
Other Maple syrup Honey and sweeteners
Turning to complex carbohydrates, several epidemiological studies have observed associations
between the consumption of refined carbohydrates and the risk of developing IBD. However, these data
are not sufficiently statistically significant to allow confirmation of this hypothesis [7]. Nonetheless,
the WSD contains many different refined carbohydrates, such as sucrose and starch found especially in
soft drinks, white bread, cakes, and desserts, all high-density energy-rich but nutrient-poor products.
In the long term, they may cause alterations of the gut microbiota and immune system, increasing the
risk for many diseases including IBD [65]. Other dietary approaches have been proposed in an attempt
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to improve IBD symptoms. These include the “specific carbohydrate diet” (SCD), first described by
Haas and co-workers in 1924 to treat celiac disease, and subsequently applied to IBD patients [66,67].
The SCD excludes gluten and complex carbohydrates since they are poorly absorbed and lead to
bacterial fermentation, which in turn induces dysbiosis in the gut lumen due to pathobiont expansion
(Table 3). Only monosaccharides such as glucose, fructose and galactose are permitted. Clinical trials,
albeit involving very few patients, reported improvements in bowel symptoms, with some patients
able to discontinue at least one of their IBD medications at the end of the SCD trial period [67].
Table 3. Carbohydrates included or excluded in the Specific Carbohydrate Diet (SCD).
Food Group Include Exclude
Fruit All fresh fruit Canned fruit (because of possible added sugars and starches)
Vegetables Fresh vegetables Canned or frozen vegetables (because of possible addedsugars and starches), potatoes and yams
Grains None All cereal grain
Legumes Certain legumes (lentils, split pea) Certain legumes (chickpeas, soybeans) and soybean “milk”
Dairy Lactose-free dairy (milk, cheese andyogurt) Milk and all dairy products
Beverage Wine Instant tea, coffee and beer
Other Honey, Corn syrup, chocolate
In conclusion, if poorly absorbed, all carbohydrates may be fermented, promoting dysbiosis and
inflammation. An excess of any kind of carbohydrate in IBD patients with intestinal malabsorption may
easily exacerbate existing intestinal dyshomeostasis, which in turn may contribute to dysmetabolism
of other nutrients, such as fats.
It is therefore reasonable to conclude that IBD diets should carefully monitor the intake of simple
and complex carbohydrates and strictly limit lactose, especially in patients intolerant to this sugar. In
fact, exclusion of specific carbohydrates (known as carbohydrate monotony) is a common feature of
the different diet-based IBD therapies, in light of the suggestion that carbohydrate variation could be
linked to IBD pathogenesis [68]. It does, however, seem unlikely that a single sub-group of foods could
be the cause of IBD.
6. Proteins
Several mechanisms of action have been postulated to explain the possible negative impact
of high protein (HP) consumption in IBD patients. One hypothesis is that the intestine’s limited
capacity to assimilate proteins, especially in IBD patients, leads to non-absorbed proteins to reach
the colonic lumen where they alter microbiota composition by reducing the abundance of bacteria
like Roseburia/E.Rectale, considered health-promoting microorganisms for their ability to produce
butyrate [69]. In fact, HP diets appear to induce IBD-like dysbiosis [70]. Rats fed a HP diet showed
increased prokaryotic protease activity, a phenomenon apparently linked to the pathogenesis of
IBD [71]. HP diets may also lead to an imbalance of metabolites of protein catabolism by colonic
bacteria (ammonium, hydrogen sulfide, p-cresol and phenol), which could damage colonocytes and the
intestinal barrier [72,73]. Several animal studies on colitis have also demonstrated that proteins derived
from red meat, milk and dairy products can exacerbate colitis. However, human epidemiological
data only partially support these findings. This is probably due to the complexity of the human diet
and diverging nutritional data collection methods [70]. In fact, two epidemiological studies have
shown a correlation between IBD and high animal protein intake derived from meat and fish but
not from eggs or dairy products, while no correlation was found with the consumption of vegetable
proteins [74,75]. Two meta-analyzes conducted in 2011 and 2015 also indicate that the consumption
of red, white and processed meat may be considered risk factors for the development of IBD [6,76].
Conversely, two more recent studies have produced conflicting results as to a correlation between meat
consumption and IBD activity. The first, by Opstelten et al. [77] involving 165 patients with IBD in
remission and 1469 healthy controls, indicated that although IBD patients eat more meat than controls,
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there was no correlation with disease exacerbation. The second study on 53 patients with active disease
and 50 in remission concluded that meat is a risk factor for active disease [77,78]. In addition to the
protein metabolism mechanism already discussed, it has also been hypothesized that the effect of meat
consumption on the onset and course of these diseases could be linked to the cooking process, which
notoriously leads to the formation of carcinogenic or mutagenic molecules such as heterocyclic amines,
acrylamide and polycyclic aromatic hydrocarbon, associated with endothelial damage and altered
immune responses [79]. However, the most convincing studies on meat and IBD have focused on the
risk of high saturated and high n-6 polyunsaturated fatty acid (PUFA) intake as a consequence of high
meat (especially red meat) consumption.
Gastro-resistant proteins are another point of attention when structuring an IBD diet since the
abundance of gastro-resistant proteins in some foods can alter intestinal permeability. Gluten is a
gastro-resistant protein complex. Its digestion gives rise to toxic and antigenic peptides (especially
alpha-gliadin peptides), which may not only interfere with the tight junction between enterocytes
but also with enterocyte survival, affecting the intestinal barrier. This, together with strong evidence
of gluten sensitivity in IBD patients [80], has led to the gluten-free diet being recommended for
IBD sufferers. Indeed, a gluten-free diet is often self-imposed by patients in an attempt to alleviate
symptoms. Ancient wheat varieties, although seemingly giving rise to similar amounts of toxic and
antigenic gluten peptides [81], have been shown to ameliorate gut and systemic inflammation in a
range of patients, including IBS sufferers [82]. For this reason, ancient varieties of low immunogenic
impact grains, such as Senatore Cappelli (Triticum turgidum durum) and Enkir (Triticum monococcum),
or a novel grain variety with low gluten immunogenicity like Tritordeum [83] should be considered for
inclusion in the IBD diet. Being gluten-free, rice has also been suggested as a complex carbohydrate
suitable for the IBD diet. This includes whole grain rice, provided it is cooked at length [84].
Milk and dairy products contain large quantities of caseins, gastro-resistant proteins known to
increase dysbiosis, inflammation and intestinal permeability in the mouse gut [85]. For this reason,
milk and dairy foods are excluded in most IBD diets and indeed, commonly restricted by IBD patients
themselves [86]. On the other hand, fermented milk products have shown positive effects on IBD
patients. Kefir was administered in a randomized controlled trial to 25 IBD patients with positive
effects on clinical parameters, such as erythrocyte sedimentation rate, C-reactive protein, bloating,
general-feeling scores, and the Lactobacillus bacterial load evaluated in patient feces [87]. Yogurt was
administered to IBD patients in a double-blind placebo-controlled clinical trial with beneficial effects on
the mean numbers of Lactobacillus, Bifidobacterium, and Bacteroides in the feces of the treated group [88].
In conclusion, although performed with only a few patients, the studies conducted so far would
seem to suggest that the IBD diet should reduce the overall amount of meat, eliminate red and processed
meat, and eliminate or greatly reduce gluten and dairy products (caseins), with the sole exception of
yogurt and kefir.
7. Fats
Recent epidemiological data attribute a protective effect to n-3 PUFAs in UC prevention and
therapy [89,90]. Conversely, consumption of higher ratios of n-6/n-3 PUFAs has been associated with
increased UC incidence. The role of n-3 PUFAs in CD prevention and therapy, however, appears
complex and controversial [89]. The physiological basis for PUFAs’ role in IBD is that the eicosanoids
produced by n-3 and n-6 PUFA are key immune response regulators, being precursors of several
pro-inflammatory (n-6 PUFA) and anti-inflammatory (n-3 PUFA) molecules. It has been demonstrated
that n-6 PUFAs are more available than n-3 PUFA for eicosanoid metabolism in the UC colon mucosa.
For this reason, dietary supplementation with n-3 PUFA, and especially eicosapentaenoic acid (EPA),
can reduce the production of prostaglandin E2, thromboxane B2 and hydroxyeicosatetraenoic acid
inflammatory mediators [91–93]. The anti-inflammatory effects of n-3 PUFA have also been linked
to the synthesis of molecules like resolvins, protectins and maresins, which counteract IBD-related
dysbiosis [94], and the down-regulation of pro-inflammatory genes [95]. However, two IBD studies
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have indicated that PUFA intake may have a different impact in CD compared to UC patients. In their
study on 137 UC patients and 38 healthy controls, Wiese and collaborators [96] showed that the
concentration of inflammatory tissue cytokines in UC patients was directly related to the amount of
serum SFAs and inversely related to total PUFAs, EPA and docosahexaenoic acid (DHA), confirming
the protective role of n-3 PUFAs in UC. But a recent study by Scoville and collaborators [97] on
116 CD patients and 27 healthy controls showed that n-3 PUFA serum concentrations were directly
related to disease severity. In particular, the authors found EPA concentration to be strongly related
to pro-inflammatory serum cytokine concentrations. This datum not only suggests that fatty acid
dysmetabolism occurs in patients with CD but also that n-3 PUFA and EPA serum levels may also
have a negative effect in CD patients. Conversely, no correlation with SFA concentration was observed
in UC patients [97]. Interestingly, both studies, which administered the same amounts of meat, total
fat, and SFA to IBD patients and healthy controls, found that n-6 PUFA/n-3 PUFA ratios were similar in
CD patients and healthy subjects, despite higher respect the WHO recommendations.
In summary, we may conclude that high fat intake should be avoided in IBD sufferers since
high fat diets may lead to an accumulation of secondary bile acids, such as deoxycholic acid, which
can inhibit Bacteroidetes and Firmicutes phyla growth, leading to IBD-like dysbiosis [7]. However,
a prospective study carried on 170,805 women showed no correlation between fat consumption and
IBD risk, but rather a positive correlation between high trans-unsaturated fat intake and UC risk [89].
In addition, the intake of n-3 PUFA and EPA in particular, within foods or supplements, may have
positive effects on health, but only for UC patients.
8. Dietary Fibers
Dietary fibers are non-digestible complex carbohydrates present in plants. They are grouped
according to their solubility or insolubility in water. Since humans lack fiber-specific enzymes, fibers
remain mainly undigested and are therefore not absorbed by the gastrointestinal tract. However, small
amounts of the ingested fibers are fermented by the bacteria in the gut, especially in the colon. Present
in fruits, vegetables, cereals and legumes, dietary fibers can exert a protective role against IBD through
four independent mechanisms [90]:
Reducing intestinal transit time;
Increasing the synthesis of SCFAs such as acetate, butyrate and propionate, which may positively
modulate intestinal inflammation;
Improving gut microbiota composition, thus counteracting IBD-related dysbiosis;
Contributing to the maintenance of intestinal barrier functions.
No conclusive studies exist evidencing the efficacy of dietary fibers in slowing IBD progression [98].
A study conducted by Andersen and collaborators [90] showed no association between average fiber
intake (total fiber, fiber from fruit, vegetables and cereals) and the subsequent development of CD
or UC. Moreover, it has been shown that fibers may exacerbate gastrointestinal (GI) symptoms,
such as abdominal distension, flatulence, constipation, and diarrhea in IBD patients during remission
periods [99]. It is therefore reasonable to postulate that a high fiber diet is not beneficial for individuals
with insufficient “fiber-degrading bacteria” in their gut microbiota [100]. However, while this type of
diet may be contraindicated for patients during disease flares, it is nonetheless highly recommended,
with appropriate adjustments, after remission in an attempt to approximate the 30g/die WHO
recommended intake.
As suggested by Eswaran and collaborators [99], patients in remission should receive a diet with
low levels of insoluble fibers, such as those in skinned vegetables like zucchini, carrots, eggplants,
green beans and chards. The vegetables should be very well cooked and consumed as a cream, at least
initially. Peeled fresh fruit is another option, providing small quantities of insoluble fiber. Putting
ingredients through a juice extractor will further reduce the amount of insoluble fiber present in fruit,
vegetables and legumes while maintaining most of the soluble fiber fraction, vitamin and mineral
content. There is also some unsubstantiated evidence that fruit and vegetable consumption may have
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a protective immune-modulating effect on IBD patients since they contain protective compounds that
may help to prevent disease flares [101]. Another source of insoluble fibers is whole grain cereals.
Here too, it seems appropriate to include cereals in the diet only after remission, doing it gradually
to avoid worsening of the disease-related GI symptoms [84,99]. Although many IBD patients avoid
foods containing fibers, this may lead to micronutrient deficiency and aggravate the malnutrition often
presented by sufferers of this disease.
9. Micronutrients
IBD patients tend to suffer from nutrient malabsorption and/or have erroneous nutritional
patterns [102], with the result that many are likely to present micronutrient, vitamin and mineral
deficiencies. Since micronutrient deficiency may affect immune system physiology and thus facilitate
disease relapse, diet or supplementation adjustment strategies could be a key to improove patients’
quality of life [103]. The main vitamin deficiencies found in IBD-patients are of fat-soluble vitamins
A (retinol and retinoids) and D, and water-soluble vitamins B12 and B9 (folic acid). Experimental
models have provided some evidence that vitamin A (provided as retinol) supplementation attenuates
intestinal inflammation and improves the gut environment, with significant benefits to health [65].
As antioxidants, vitamins A have a probable protective role against free radicals and oxidative damage,
both of which are increased in these patients [104].
As well as regulating bone, calcium, and phosphorus metabolism, Vitamin D has a key role in
intestinal defense mechanisms, regulating the adaptive and innate immune systems and suppressing
microbial invasion of the epithelium [105,106]. Vitamin D deficiency has been detected in 16% to 95%
of IBD sufferers, mainly in CD patients [107]. This may be due to several factors, such as intestinal
malabsorption, low exposure to sunlight, lack of physical activity, or insufficient dietary intake. Therapy
targeting the vitamin D3 signaling pathway has been suggested in IBD since it may regulate both
innate and adaptive immune functions. However, the overall effect of vitamins on IBD is still not
well understood, and the clinical studies performed have shown contrasting results. A Danish study
conducted between 2005 and 2008 randomized 94 IBD patients to receive oral vitamin D3 or placebo.
Although patients receiving vitamin D3 showed a reduced risk of clinical relapse (from 29% to 13%),
this was not statistically significant [108]. Similarly, a more recent Iranian study on 108 IBD patients
found that oral vitamin D3 supplementation gave rise to lower serum TNF levels, which, however,
were also not statistically significant [109].
Folic acid, or folate, is available in several vegetables and is absorbed in the duodenum and
proximal jejunum. Both micronutrients are essential for cell metabolism, and folate deficiency is
often correlated with vitamin B12 deficiency, this latter mainly available in animal products. Despite
their ample availability in food, folate and vitamin B12 absorption occurs in areas often damaged by
phlogosis, which may be the cause of impaired uptake in IBD-patients [110].
Trace elements are another important avenue of ongoing research into the prevention and control
of IBD. Iron deficiency is very frequent in IBD and the leading cause of anemia among IBD patients.
In a recent study, 27% of all CD and 21% of all UC patients were found to have anemia [111]. An iron-,
heme- and nonheme-rich diet or oral/parenteral supplementation is therefore mandatory. However,
iron—and especially ferrous sulfate—is a known pro-oxidative agent, raising concern that oral iron
may increase oxidative stress in patients with colitis [112].
Zinc is an essential micronutrient, an enzyme co-factor involved in cellular immunity, cell growth
and wound healing. Zinc deficiency has been associated with excessive loss of GI secretions due to
chronic diarrhea or fistula drainage in IBD patients. Prevalent in 15% to 40% of IBD patients, it has also
been associated with hospitalization, surgery and other disease complications [113].
Selenium is a non-metal trace element existing in both the inorganic and organic form. It is
translationally incorporated as selenocysteine into selenoproteins, which can modulate various cellular
pathways involved in inflammation. Adequate selenium intake is thus essential for normal immune
functions [114]. In fact, selenium deficiency has been correlated with gastrointestinal inflammation and
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altered gut microbiota composition [115]. Epidemiological studies suggest that selenium serum levels
are inversely correlated with IBD incidence. Moreover, selenium blood concentrations were found to
be significantly lower in Caucasians and Asiatic IBD patients, especially in CD [116,117]. Although
further studies are necessary to assess the mechanism underlying the effect of selenium deficiency in
IBD, it would seem important to ensure adequate selenium intake in all IBD patients.
10. Food Additives and Ultra-Processed Food
Ultra-processed foods (NOVA 4 classification) are the result of a series of industrial processes,
many requiring sophisticated equipment and technology. Ultra-processed food manufacture entails
fractioning whole foods into different substances, their chemical modification and subsequent assembly
with other modified and unmodified food products. The industrial techniques used include extrusion,
molding, pre-frying, and the addition of “cosmetic” palatability additives [50]. The presence of high
levels of ultra-processed food in the diet has already been linked to a number of non-communicable
diseases including cancer, obesity and type 1 and 2 diabetes [118–120]. Despite this, however, the role
of these foods on the intestinal microbiota, and on IBD in particular, has never been investigated.
However, there is well-documented scientific evidence of the negative effects on the microbiota of food
additives typically present in a considerable number of ultra-processed foods. Various studies have
clearly shown the negative effect of non-caloric artificial sweeteners often present in carbonated soft
drinks on microbiome composition and functioning [121]. The sweetener sucralose has been shown to
reduce the relative amount of Clostridium cluster XIVa in mice feces [122]. Dietary emulsifiers have
also been shown to directly alter human microbiota composition and gene expression in an ex vivo
model [123], while maltodextrins, commonly used for the production of soft drinks, candy and sport
energy products, have been found to cause microbiota alterations [124] and affect gut epithelial cells,
reducing mucus production and exacerbating gut inflammation [125].
The commonly used food additive carrageenan has been shown to induce intestinal inflammation
in animal models. Although there is little evidence of the role carrageenan may play in the development
of IBD since direct carrageenan assessment trials in man are unethical, animal studies have clearly
demonstrated that this additive induces IBD-like histopathological features, alters the microbiome, and
disrupts the intestinal epithelial barrier [126]. Red meat, eggs naturally contain high levels of sulfites
due to their high cysteine content, which can become a substrate for the production of hydrogen sulfide
(H2S) by sulfate-reducing bacteria. However, sulfites are also abundantly used as food additives to
limit bacterial contamination. Generally considered safe for human consumption, they are present
in food and alcoholic beverages in quantities up to 5000 parts per million (ppm). However, even at
lower concentrations, sulfites have been shown to damage beneficial bacteria, such as Lactobacillus and
S. thermophilus in the human gut [127]. Sulfites can be produced by intestinal microbiota even starting
from taurine (from the bacterium B. wadsworthia) which is a typical ingredient of energy drinks or
from chondroitin sulfate, a widely used food supplement in the treatment of osteoarthritis [128]. Some
studies have found that patients with UC show a higher production of H2S in the gut, but it is not clear
whether this increased synthesis is simply linked to the increased intestinal inflammation [128].
11. Alcohol
Small quantities of alcohol are first metabolized in the stomach. Larger amounts are absorbed
in the small intestine and may reach the large bowel from the bloodstream where it is metabolized
by luminal bacterial alcohol dehydrogenase, producing the toxic compound acetaldehyde [129,130].
Severe dysbiosis has been associated with chronic alcohol abuse. In addition, the high sugar content of
some alcoholic drinks may be associated with osmotic diarrhea [131]. A study of 52 Crohn’s and 38 UC
patients with an alcohol consumption pattern similar to the general population found that although
75% of the IBD patients reported worsening of their symptoms, this could not be related to alcohol
intake [132]. In 2018, a prospective cohort study of 262,451 subjects enrolled in six countries showed
no association between alcohol use and the onset of IBD [133]. Interestingly, two studies have found
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a correlation between UC disease activity and sulfite, an additive commonly used also in processed
alcoholic drinks [134,135]. In conclusion, although there are insufficient data to define alcohol as a risk
factor for IBD, its toxic effect on colon mucosa strongly suggests limiting alcohol intake in IBD sufferers.
12. Nutritional approach in IBD
Recently, numerous new dietary philosophies have become popular. These include the paleo
and the vegan diets, often recommended in the management of gastrointestinal diseases such as IBD.
However, there is no clinical evidence to support their use in IBD [113]. The only nutritional approach
with strong evidence of efficacy is Exclusive Enteral Nutrition (EEN), a diet based on foods classified
according to their nitrogen content as: elemental (amino acid based), semi-elemental (oligopeptide
based) and polymeric (whole protein based). EEN has proved as efficacious as steroid treatment in
inducing remission of CD in children and adults but not of UC [136]. Although the above-mentioned
low FODMAPs diet has been mainly used to alleviate symptoms in IBS patients, there are currently
no consistent data supporting its use in IBD. A pilot study conducted on 52 CD and 20 UC patients
showed that 50% of patients had an improvement in abdominal pain, bloating, and diarrhea [137].
A double-blind controlled placebo cross-over trial was conducted with 32 patients with quiescent
disease and IBS-like symptoms that had proved responsive to a Low-FODMAP diet. Patients were
randomly assigned to receive fructans, galacto-oligosaccharides, sorbitol, glucose or placebo. The study
found that only fructans exacerbated symptoms in patients, which casts into question the real usefulness
of the low FODMAPs diet in IBD [138]. Another uncontrolled clinical trial included a semi-vegetarian
diet as an “add-on therapy” to the biological drugs used to induce remission. 26 adults and 11 children
with recently diagnosed CD and 9 adults with relapsing CD received a lacto-ovo semi-vegetarian
diet that included fish once a week and meat once every 2 weeks. Results showed an increase of the
expected remission rate in all patients [139]. Yet another study of CD patients on a semi-vegetarian
diet for two years reported the absence of CD relapse in 15 of the 16 patients treated [140]. The IgG
exclusion diet, on the other hand, is a personalized regime based on preliminary blood titration of food
IgG. Two studies conducted by the same research group have demonstrated the efficacy of this diet.
The first, an open-label pilot study, was conducted on 40 symptomatic CD patients [141] while the
second was a randomized study enrolling 76 subjects with active CD. In this second study, the foods
most frequently excluded were milk, beef, pork and eggs. The personalized diet significantly improved
patients’ quality of life and disease activity, measured using the Crohn’s Disease Activity Index (CDAI)
and Harvey-Bradshaw Index (HBI) [142].
Although SCD diet is one of the most popular among IBD patients, it has many restrictions making
compliance difficult. Obih and collaborators [143] conducted a retrospective study on 26 IBD children
who had followed the SCD for 3–48 months, 18 of whom were receiving concomitant medication
therapy. 12 of the 26 patients showed improvements in their clinical and inflammatory markers.
It should, however, be noted that in the medium and long term the SCD diet may cause adverse
effects, such as weight loss and nutritional deficiencies. Patients following this diet must therefore be
carefully monitored.
Another study on the SCD, involving 50 adult IBD (mainly colonic CD) patients, obtained a better
symptom score and a higher quality of life. Some patients were even able to maintain clinical remission
without medication [144]. The fecal microbiota of patients on the SCD was observed to have a higher
biodiversity index compared to matched patients eating a WSD [144]. These data suggest that the SCD
may be a good starting point from which to plan a dietary regime for IBD patients, especially in the
maintenance phase.
13. Conclusions
Although the study data are still often unsubstantiated, it is important not to underestimate the
role diet can play in supporting conventional IBD therapies, not only helping to induce and maintain
clinical remission, but above all, improving patient quality of life.
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While controversy still surrounds the exact role played by diet in the development of IBD,
there are indications that diet may significantly modulate disease onset and activity. No formal dietary
guidelines exist, however, for patients with IBD. The wide variability of study results is due in part
to the design limitations of what are largely underpowered, retrospective studies, and in part to the
heterogeneous disease subtypes (UC, CD) recruited to the studies.
The complexity of the human diet makes it very difficult to identify individual foods as risk
factors. It is in fact more likely that complex nutritional patterns very different from either the
traditional Mediterranean diet or other traditional diets matching our evolutionary status may impact
pathogenesis and the clinical course of IBD. In evolutionary terms, in fact, people in industrialized
countries can be described as nutritionally mismatched and more susceptible - to degrees depending
on their genetic background - the many non-communicable diet-related diseases, including IBD.
We now know the mechanisms of action whereby certain food groups may have a negative impact
on the microbiota, triggering intestinal inflammation or intestinal permeability. We also know that the
Western population tends to eat excessive amounts of “dangerous” foodstuffs. As mentioned above,
the reason why studies have failed to provide strong evidence of dietary efficacy could be due to
individual variability as well the small patient series studied. However, as one of the factors involved
in the onset and progression of IBD, diet requires further in-depth study, especially since IBD patients
tend to have disordered and unbalanced eating patterns. Although guidelines on IBD prevention
and treatment are starting to appear (Figure 4) [60], it must be remembered, however, that they are
based more on logical assumptions and animal models than on evidence provided by broad controlled
human clinical studies.
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Carbohydrates: White rice, 
basmati rice, rice noodles, oats, 
ancients grains bread and pasta, 
fresh potatoes (frozen potatoes 
or chips are not allowed) 
 
Fresh chicken, fresh fish, eggs. 
Once a week fresh unprocessed 
beef steak (lean meat) 
 
Peeled fruit and vegetables: 
tomatoes, cucumbers, carrot 
fresh spinach (side portion), 
zucchini, apple (if no tight 
stricture), bananas, few 
strawberry, kiwi, slice melon 
Fresh onion or garlic or ginger 
 
Condiments: Olive oil, canola oil, 
pepper, paprika, cinnamon stick  
 
Fresh herbs: mint leaves, 
oregano, coriander, rosemary, 
sage, basil, thyme 
 
Beverages: water, herbal tea, 
freshly squeezed orange or 
lemon juice daily (not from 
cartons or bottles), and 
vegetables drinks and 
Lactose-free or fermented dairy 
products (kefir, yoghurt and low 
amount of milk), vegetal milks 
(almond, coconut, rice, or oat), 
low amounts of hard (goat or 
sheep) cheese 
 
Sugars : true hard honey 
 
 
Refined carbohydrates: 
Wheat, breakfast cereals,  
bread for toast of any kind,   
pizza , gluten-free industrial 
products  
 
Processed or smoked meats 
and fish: sausages, lunched 
meats, salami, fish sticks 
Dairy products: Cow, goat, 
sheep milk, cow cheese, 
buttermilk, soft cheese, cream 
and ice cream. 
 
Legumes: Beans, chickpeas, 
soybeans and soymilk 
 
Condiments: salt, margarine 
sauces, salad dressing, syrup, 
jam of any kind 
 
Canned products, canned 
fruits and canned or frozen 
vegetables 
 
Packaged snacks: potato 
snacks, popcorn, nuts snacks. 
 
Candies, cake and dessert, 
milk-chocolate 
 
Beverages: all soft drinks, all 
sport energy drinks, beer, 
alcoholic drinks, fruit juices, 
instant tea and coffee 
preparations 
 
Sugars: sorbitol, mannitol, 
xylitol and maltitol , corn syrup 
 
Food additives: sucralose, 
emulsifiers, maltodextrins, 
carrageenan, sulfites 
 
 
 
 
 
 
Carbohydrates: Whole rice, whole red and black 
rice 
 
Legumes: lentils, split peas, soybean sprouts 
 
Beverages: Espresso or American coffee, wine 
 
Sugars: table sugar (max 2-3 teaspoons a day for 
permitted beverages) 
 
Dark chocolate (Cocoa minimum 80%) 
 
Figure 4. A possible diet for IBD: dietary foods and factors potentially affecting positively or negatively
host intestinal barrier, immunity and microbioma in IBD patients.
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